Bangkok Genomics Innovation PCL (BKK:BKGI) Net Cash per Share : ฿0.58 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Bangkok Genomics Innovation PCL's Net Cash per Share for the quarter that ended in Mar. 2024 was ฿0.58.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's Net Cash per Share or its related term are showing as below:

BKK:BKGI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.86 Med: 5.83 Max: 5.83
Current: 4.86

During the past 5 years, the highest Price-to-Net-Cash Ratio of Bangkok Genomics Innovation PCL was 5.83. The lowest was 4.86. And the median was 5.83.

BKK:BKGI's Price-to-Net-Cash is ranked better than
60.81% of 74 companies
in the Medical Diagnostics & Research industry
Industry Median: 6.97 vs BKK:BKGI: 4.86

Bangkok Genomics Innovation PCL Net Cash per Share Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL Net Cash per Share Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

-0.07

0.02

0.16

0.18

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial			-	0.16	0.15	0.18	0.58

Competitive Comparison of Bangkok Genomics Innovation PCL's Net Cash per Share

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Genomics Innovation PCL's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's Price-to-Net-Cash falls into.

Bangkok Genomics Innovation PCL Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Bangkok Genomics Innovation PCL's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(165.905	-	57.202	-	0)	/	600
=	0.18

Bangkok Genomics Innovation PCL's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(399.167	-	52.363	-	0)	/	600
=	0.58

Bangkok Genomics Innovation PCL (BKK:BKGI) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Bangkok Genomics Innovation PCL Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).